Date: 2017-01-03
Type of information: Opening of new premises
Compound: cell therapies manufacturing center
Company: BioTime (USA - CA) Cell Cure Neurosciences (Israel)
Therapeutic area: Ophtalmological diseases
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On January 3, 2017, BioTime a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, and its majority-owned subsidiary, Cell Cure Neurosciences dedicated a new, 800 square meter (8,600 square feet), state-of-the-art, cGMP manufacturing center located in the Jerusalem Bio Park on the campus of Hadassah University Hospital in Jerusalem. The new manufacturing center, initially to be staffed by 25-30 employees, is equipped to produce a range of cell therapies for the treatment of various degenerative human diseases. In the near term, the plan is to supply Opregen® for the company’s ongoing clinical trial program for the treatment of dry age-related macular degeneration, or dry AMD. OpRegen provides a particular cell type in the retina, called Retinal Pigment Epithelial cells, to replace those lost due to the disease. Data presented at the ISOPT Clinical Symposium on December 2, 2016, indicate that OpRegen at the first dose caused no serious adverse events in the first patient cohort and retinal imaging suggests the presence and survival of the transplanted cells in the subretinal space for up to one year.
Financial terms:
Latest news:
